Skip to main content

Coloplast A/S (CBHD.DE)

Frankfurt Stock Exchange (XETRA) Healthcare Medical - Equipment & ServicesView data quality →
58.1Fair

ValueMarkers Composite Index

Top 72%#12,562 of 44,714
Slightly Overvalued

13% above intrinsic value ($10)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.20
Investigate
Altman
1.94
Grey Zone
DCF Value
$10
Undervalued
ROIC
10.9%
Adequate
P/E
24.0
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Coloplast A/S (CBHD.DE) — VMCI valuation read

Coloplast A/S sits at VMCI 58/100, with the Healthcare sector median at 50. That 8-point spread is the first thing to note on CBHD.DE: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on CBHD.DE are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on CBHD.DE: CBHD.DE trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 2.9x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

CBHD.DE fell 0.5% over the trailing 7 days, with a -20.4% read on a 30-day basis.

Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.

CEO: Lars Soren Rasmussen16,741 employeesDKwww.coloplast.dk

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in CBHD.DE’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.